The San Diego Biotech Survival Index: Local Firms Make Strong Rebound In First Half of 2009

9/23/09Follow @xconomy

(Page 3 of 4)

Hollis-Eden Pharmaceuticals (NASDAQ: HEPH)
Cash on hand: $15.2 million
Previous Xconomy coverage:
San Diego Biotech Hollis-Eden Terminates CEO

Illumina (NASDAQ: ILMN)
Cash on hand: $790 million
Previous Xconomy coverage:
Illumina Sales Miss Expectations
Illumina Shows Its Stuff to Wall Street, Stock Still Slides

Inovio Biomedical (AMEX: INO)
Cash on hand: $8.3 million
Previous Xconomy coverage:
Inovio, Fuelled by Swine Flu Fear, Reinvents Itself as Developer of Universal Flu Vaccines

Isis Pharmaceuticals (NASDAQ: ISIS)
Cash on hand: $637.5 million
Previous Xconomy coverage:
Isis, Genzyme Use Antisense to Go Where Many Drugs Fail, the Brain
Genzyme, Isis Cholesterol Drug Reaches Goal in Pivotal Study, Paving the Way to FDA
Isis Pharmaceuticals Second Drug Aims to Block Marker of Heart Disease, Inflammation
Alnylam, Isis Offspring, Regulus, Keeps Pushing on Biology’s Bleeding Edge

Life Technologies (NASDAQ: LIFE)
Cash on hand: $582 million
Previous Xconomy coverage:
From Merger of Invitrogen and Applied Biosystems, Life Technologies Plans to Grow From San Diego Base

Ligand Pharmaceuticals (NASDAQ: LGND)
Cash on hand: $55.5 million
Previous Xconomy coverage:
Ligand Gets Neurogen for $11 Million
Ligand Cuts Another Deal With GlaxoSmithKline

To purchase a much expanded version of this report, in PDF format, click the “Add to Cart” button.
For $95,* you’ll get an assessment of each company’s financial position at the end of June compared to six months earlier, the projected length of time it can survive on its existing cash reserves, and an analysis of the strategic moves it has made to stay afloat in the current environment. Click here to see a sample entry. Add to Cart
*Price is subject to change without notice.

Metabasis Therapeutics (NASDAQ: MBRX)
Cash on hand: $6.6 million
Previous Xconomy coverage:
Ailing Metabasis Hires Advisory Firm
Metabasis Therapeutics Restructures, Cuts 38 From Staff
Latest Metabasis Cutbacks Leave Just Seven Employees

Neurocrine Biosciences (NASDAQ: NBIX)
Cash on hand: $74 million
Previous Xconomy coverage:
$75M Financing for Neurocrine
Neurocrine Cuts Half of Workforce
… Next Page »

Single Page Currently on Page: 1 2 3 4 previous page

By posting a comment, you agree to our terms and conditions.